Dr Handrean Soran is Consultant Physician and Endocrinologist & Honorary Senior Lecturer at Manchester University Trust. He has a specialist interest in lipidology, atherosclerosis, cardiovascular risk, parathyroid, calcium and bone metabolism. He provides a tertiary centre service for lipoprotein disorders, as well as calcium and metabolic bone diseases. His research work is mainly focused on cardiovascular risk, low-density lipoprotein (LDL) quality, high-density lipoprotein (HDL) functionality, micro- and macro-vascular complications of diabetes & obesity and the effect of metabolic surgery induced weight loss as well as pharmacological agents on these complications. Dr Soran is on the editorial board of Atherosclerosis Journal. Dr Soran authored more than 145 peer reviewed publications and a number of book chapters.
Dr Soran leads cardiovascular and trials team and Lipid Research group at Manchester University NHS Trust and Lipoprotein Research Group at University of Manchester. He acted as the UK chief investigator for more than 15 multicentre clinical trials and principal investigator for more than 25 multicentre clinical trials and studies. He also acted as a member of the steering committee of many large multinational randomised control trials.
He successfully supervised many MD and PhD students and currently has one MD and four PhD students. Dr Soran Leads Manchester Endocrinology and Diabetes Specialty Certificate Examination (SCE) course which attracts many national and international delegates. He also organises annual UK Lipid Forum and North West Endocrinology and Atherosclerosis update symposiums. Each of these annual symposiums attracts 120-150 delegates across United Kingdom.
Dr Soran is the Chair of HEART UK’s medical, scientific and research committee, co-chair of the National Familial Hypercholesterolemia task force in UK, a member of UK lipoprotein apheresis committee and European Atherosclerosis Society’s Familial Hypercholestrolaemia Collaborative Study (FHSC) executive committee. He also served as the President of the Lipid, Metabolism and Vascular Section of the Royal Society of Medicine and remains a member of the section’s council.